Active, not recruitingPhase 2NCT05952037
A Study to Investigate Efficacy and Safety of BCL2 Inhibitor Sonrotoclax as Monotherapy and in Combination With Zanubrutinib in Adults With Waldenström Macroglobulinemia
Studying Waldenström Macroglobulinemia
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- BeOne Medicines
- Principal Investigator
- Study DirectorBeOne Medicines
- Intervention
- Sonrotoclax(drug)
- Enrollment
- 114 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2023 – 2028
Study locations (30)
- City of Hope National Medical Center, Duarte, California, United States
- Colorado Blood Cancer Institute, Denver, Colorado, United States
- Medstar Georgetown University Hospital, Washington D.C., District of Columbia, United States
- University of Miami, Miami, Florida, United States
- Northwestern Medicine Cancer Center, Warrenville, Illinois, United States
- Mission Cancer and Blood, Waukee, Iowa, United States
- University of Maryland Greenebaum Comprehensive Cancer Center, Baltimore, Maryland, United States
- Dana Farber Cancer Institute, Boston, Massachusetts, United States
- Mayo Clinic Rochester, Rochester, Minnesota, United States
- Hattiesburg Hematology and Oncology Clinic, Hattiesburg, Mississippi, United States
- Memorial Sloan Kettering Cancer Center Mskcc, New York, New York, United States
- Atrium Health Levine Cancer Institute (Lci), Charlotte, North Carolina, United States
- Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States
- Ut Southwestern Medical Center, Dallas, Texas, United States
- Huntsman Cancer Institute, Salt Lake City, Utah, United States
- +15 more locations on ClinicalTrials.gov
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT05952037 on ClinicalTrials.govOther trials for Waldenström Macroglobulinemia
Additional recruiting or active studies for the same condition.
- RECRUITINGNANCT07471074Phenotypic and Functional Study of Bone Marrow Mesenchymal Stem Cells in Waldenström MacroglobulinemiaCentre Hospitalier Universitaire, Amiens
- RECRUITINGPHASE2NCT06986174A Phase 2 Study to Evaluate the Safety and Efficacy of Pacritinib in Relapsed or Refractory Waldenström MacroglobulinemiaShayna Sarosiek, MD
- RECRUITINGPHASE4NCT07169331A Study to Evaluate the Efficacy and Safety of Zanubrutinib in Chinese Adults With Treatment-Naive Waldenström MacroglobulinemiaBeiGene
- RECRUITINGPHASE2NCT05734495Pirtobrutinib and Venetoclax in Waldenström MacroglobulinemiaDana-Farber Cancer Institute
- RECRUITINGNCT05640102Observational Study Evaluating the Efficacy and Safety of Zanubrutinib in Participants With Waldenström MacroglobulinemiaBeiGene
- RECRUITINGNANCT04893564Prognostic Value of Circulating Tumoral DNA After the First 6 Months of Treatment in Patients With Waldenström MacroglobulinemiaCentre Hospitalier Universitaire, Amiens
- RECRUITINGNANCT04898647Clinical Study of the Hyperviscosity Syndrome in Waldenström MacroglobulinemiaCentre Hospitalier Universitaire, Amiens
- ACTIVE NOT RECRUITINGPHASE2NCT02180724An Open-label, Phase 2 Study of ACP-196 in Subjects With Waldenström MacroglobulinemiaAcerta Pharma BV